De Novo
DEN200038: Gili Pro BioSensor (also known as “Gili BioSensor System”)
FDA De Novo · continuse biometrics ltd. · decided Apr 1, 2021
Key facts
| De Novo number | DEN200038 |
|---|---|
| Device name | Gili Pro BioSensor (also known as “Gili BioSensor System”) |
| Applicant | continuse biometrics ltd. |
| Product code | QOK |
| Date received | Jun 12, 2020 |
| Decision date | Apr 1, 2021 |
| Decision | granted (DENG) |
| FDA classification | Class II |
| Review panel | Cardiovascular |
| FEI number | 3768 |
At a glance
- None Later 510(k)s citing this De Novo
- None UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
- No Decision summary on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About De Novo classification requests
The De Novo pathway classifies novel low- to moderate-risk devices that have no legally marketed predicate; each granted request creates a new classification regulation and product code.
Source: U.S. Food and Drug Administration (FDA), De Novo database · Source date: